Combining chemotherapy and targeted therapies in metastatic colorectal cancer

被引：27

作者：

Rodriguez, J. ^{[1
]}

Zarate, R. ^{[1
]}

Bandres, E. ^{[1
]}

Viudez, A. ^{[1
]}

Chopitea, A. ^{[1
]}

Garcia-Foncillas, I. ^{[1
]}

Gil-Bazo, I. ^{[1
]}

机构：

[1] Univ Navarra, Dept Oncol, Ctr Appl Med Res, Clin Univ,Unit Res & Treatment Gastrointestinal M, E-31080 Pamplona, Spain

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2007年 / 13卷 / 44期

关键词：

targeted therapy; chemotherapy; combinations; clinical trials; colorectal cancer;

D O I：

10.3748/wjg.v13.i44.5867

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Colorectal cancer remains one of the major causes of cancer death worldwide. During the past years, the development of new effective treatment options has led to a considerable improvement in the outcome of this disease. The advent of agents such as capecitabine, irinotecan, oxaliplatin, cetuximab and bevacizumab has translated into median survival times in the range of 2 years. Intense efforts have focused on identifying novel agents targeting specific growth factor receptors, critical signal transduction pathways or mediators of angiogenesis. In addition, several clinical trials have suggested that some of these molecularly targeted drugs can be safely and effectively used in combination with conventional chemotherapy. In this article we review various treatment options combining cytotoxic and targeted therapies currently available for patients with metastatic colorectal cancer. (C) 2007 WJG. All rights reserved.

引用

页码：5867 / 5876

页数：10

共 50 条

[1] Combining chemotherapy and targeted therapies in metastatic colorectal cancer
J Rodriguez
R Zarate
E Bandres
A Viudez
A Chopitea
J García-Foncillas
I Gil-Bazo
World Journal of Gastroenterology, 2007, (44) : 5867 - 5876
[2] More is less—combining targeted therapies in metastatic colorectal cancer
Cornelis J. A. Punt
Jolien Tol
Nature Reviews Clinical Oncology, 2009, 6 : 731 - 733
[3] OPINION More is less-combining targeted therapies in metastatic colorectal cancer
Punt, Cornelis J. A.
Tol, Jolien
NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (12) : 731 - 733
[4] A role of targeted therapies combined with chemotherapy in the outcome of metastatic colorectal cancer in the clinical pratice
Schirone, Alessio
Carandina, Ilaria
Matteucci, Laura
Marzola, Marina
Lelli, Giorgio
EUROPEAN JOURNAL OF ONCOLOGY, 2010, 15 (01): : 33 - 41
[5] Combining targeted therapies to enhance the effectiveness of chemotherapy in patients with treatment-refractory colorectal cancer
Eng, Cathy
CLINICAL COLORECTAL CANCER, 2007, 6 : S53 - S59
[6] Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer
Jones, Jeremy C.
Ciombor, Kristen K.
Wu, Christina
Bekaii-Saab, Tanios S.
Strickler, John
ONCOLOGY-NEW YORK, 2021, 35 (10): : 654 - 660
[7] Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
Koehne, Claus-Henning
Lenz, Heinz-Josef
ONCOLOGIST, 2009, 14 (05): : 478 - 488
[8] Integration of Targeted Therapies With Cytotoxic Chemotherapy in the Treatment of Colorectal Cancer
Chu, Edward
CLINICAL COLORECTAL CANCER, 2010, 9 : S6 - S6
[9] Combining chemotherapy and targeted therapies against resistance and recurrence in ovarian cancer
Fernandez-Ramires, R.
Herreros, E.
Vilos, C.
Bravo, M. L.
Otero, C.
Morales, S.
Velasquez, L.
Owen, G.
FEBS JOURNAL, 2013, 280 : 304 - 305
[10] Combining drug therapies to improve treatment efficacy in metastatic colorectal cancer
Isobel Leake
Nature Reviews Gastroenterology & Hepatology, 2015, 12 (3) : 121 - 121

← 1 2 3 4 5 →